{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:14:26Z","timestamp":1768709666853,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,16]],"date-time":"2011-04-16T00:00:00Z","timestamp":1302912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00417-011-1650-8","type":"journal-article","created":{"date-parts":[[2011,4,16]],"date-time":"2011-04-16T04:37:55Z","timestamp":1302928675000},"page":"1065-1071","source":"Crossref","is-referenced-by-count":20,"title":["Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension"],"prefix":"10.1007","volume":"249","author":[{"name":"The TATS (Travatan Adjunctive Treatment Study) group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,16]]},"reference":[{"key":"1650_CR1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"AGIS Investigators. The Advanced Glaucoma Study Group (AGIS)","year":"2000","unstructured":"AGIS Investigators. The Advanced Glaucoma Study Group (AGIS) (2000) The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429\u2013440","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1650_CR2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0149-2918(04)90008-2","volume":"26","author":"HB Dubiner","year":"2004","unstructured":"Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J (2004) Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 26(1):84\u201391","journal-title":"Clin Ther"},{"key":"1650_CR3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1185\/030079906X120904","volume":"22","author":"W Franks","year":"2006","unstructured":"Franks W, Group BS (2006) Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic suspension 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 22:1643\u20131649","journal-title":"Curr Med Res Opin"},{"key":"1650_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajo.2004.04.058","volume":"138","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN (2004) An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 138:19\u201331","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1650_CR5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1185\/030079906X120959","volume":"22","author":"J Garcia-Feijoo","year":"2006","unstructured":"Garcia-Feijoo J, de la Martinez Casa JM, Castillo A, Mendez C, Fernandez-Vidal A, Garcia S\u00e1nchez J (2006) Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22(9):1689\u20131697","journal-title":"Curr Med Res Opin"},{"key":"1650_CR6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00061198-200110000-00010","volume":"10","author":"I Goldberg","year":"2001","unstructured":"Goldberg I, Cunha-Vaz J, Jakobson JE et al (2001) Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 10:414\u2013422","journal-title":"J Glaucoma"},{"key":"1650_CR7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/112067210601600606","volume":"16","author":"G Hollo","year":"2006","unstructured":"Hollo G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B, Berta A, Szaflik J, Turcli E, Stewart WC (2006) The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 16:816\u2013823","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"1650_CR8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1185\/03007990802159273","volume":"24","author":"G Hollo","year":"2008","unstructured":"Hollo G, Kothy P (2008) Intraocular pressure reduction with travoprost\/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin 24(6):1755\u20131761","journal-title":"Curr Med Res Opin"},{"key":"1650_CR9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ophtha.2004.11.032","volume":"112","author":"AG Konstas","year":"2005","unstructured":"Konstas AG, Karabatsas CH, Lallos N, Georgiadis N et al (2005) 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma. Ophthalmology 112:603\u2013608","journal-title":"Ophthalmology"},{"key":"1650_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0002-9394(14)76896-5","volume":"111","author":"LK Mao","year":"1991","unstructured":"Mao LK, Stewart WC, Shields MB (1991) Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 111:51\u201355","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1650_CR11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1185\/030079904125004529","volume":"20","author":"JM Mart\u00ednez de la Casa","year":"2004","unstructured":"Mart\u00ednez de la Casa JM, Castillo A, Garc\u00eda Feijoo J, M\u00e9ndez Hern\u00e1ndez C, Fern\u00e1ndez Vidal A, Garc\u00eda S\u00e1nchez J (2004) Concomitant administration of travoprost and brinzolamide versus fixed latanoprost\/timolol maleate combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin 20(9):1333\u20131339","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1650_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/IJG.0b013e31815072fe","volume":"17","author":"K Miura","year":"2008","unstructured":"Miura K, Ito K, Okawa C, Sugimoto K, Matsunaga K, Uji Y (2008) Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma 17(3):233\u2013237","journal-title":"J Glaucoma"},{"key":"1650_CR13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","volume":"132","author":"PA Netland","year":"2001","unstructured":"Netland PA, Landry T, Sullivan EK et al (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132:472\u2013484","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1650_CR14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02850202","volume":"20","author":"PA Netland","year":"2003","unstructured":"Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA, Travoprost Study Groups (2003) Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 20(3):149\u2013163","journal-title":"Adv Ther"},{"issue":"5","key":"1650_CR15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1046\/j.1532-5415.2002.50226.x","volume":"50","author":"GD Novack","year":"2002","unstructured":"Novack GD, O\u2019Donnell MJ, Molloy DW (2002) New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc 50(5):956\u2013962","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"1650_CR16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9394(01)01257-0","volume":"132","author":"S Orengo-Nania","year":"2001","unstructured":"Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA (2001) Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 132(6):860\u2013868","journal-title":"Am J Ophthalmol"},{"key":"1650_CR17","first-page":"2566","volume":"41","author":"N Orzalesi","year":"2000","unstructured":"Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A (2000) Effect of timolol, latanoprost and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41:2566\u20132573","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1650_CR18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00417-002-0553-0","volume":"240","author":"N Pfeiffer","year":"2002","unstructured":"Pfeiffer N, European Latanoprost Fixed Combination Study Group (2002) A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 240:893\u2013899","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1650_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2006.04.007","volume":"28","author":"R Reis","year":"2006","unstructured":"Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L (2006) A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 28:552\u2013559","journal-title":"Clin Ther"},{"key":"1650_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1185\/030079905X38222","volume":"21","author":"N Shoji","year":"2005","unstructured":"Shoji N, Ogata H, Suyama H, Ishikawa H, Suzuki H, Morita T, Kawai H, Nishimoto H, Nemoto T, Shimizu K (2005) Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 21:503\u2013507","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1650_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/106002809603000109","volume":"30","author":"SJ Sorensen","year":"1996","unstructured":"Sorensen SJ, Abel SR (1996) Comparison of the ocular beta-blockers. Ann Pharmacother 30(1):43\u201354","journal-title":"Ann Pharmacother"},{"issue":"9","key":"1650_CR22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.eye.6701353","volume":"18","author":"WC Stewart","year":"2004","unstructured":"Stewart WC, Day DG, Stewart JA et al (2004) Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 18(9):905\u2013910","journal-title":"Eye"},{"issue":"24","key":"1650_CR23","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198206173062412","volume":"306","author":"T Williams","year":"1982","unstructured":"Williams T, Ginther WH (1982) Hazard of ophthalmic timolol maleate. N Engl J Med 306(24):1485\u20131486","journal-title":"N Engl J Med"},{"key":"1650_CR24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bjo.85.8.983","volume":"85","author":"WY Zhang","year":"2001","unstructured":"Zhang WY, Li Wan Po A, Dua HS, Azuara-Blanco A (2001) Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85:983\u2013990","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-011-1650-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-011-1650-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-011-1650-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T03:19:17Z","timestamp":1560136757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-011-1650-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,16]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s00417-011-1650-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,16]]}}}